Daniel J. George, MD: This case involves a 48-year-old gentleman who presented to his local physician complaining of some back pain and some right flank pain. He was found, on evaluation with a CT scan, to have a large right renal cell renal mass, as well as significant retroperitoneal adenopathy and evidence of a mass on his left adrenal gland, as well as a lytic lesion in his T9 vertebral body. This is very suspicious for renal cell carcinoma on presentation at stage IV metastatic. Because of the presence of the lytic lesion in his T9 vertebral body, palliative radiation therapy was performed first, after a biopsy confirmation of the renal cell carcinoma.
Following palliative radiation to his spine, the patient underwent a debulking nephrectomy, removing his renal tumor out of his kidney, as well as multiple lymph nodes. Pathology from this revealed clear-cell carcinoma consistent with a renal cell carcinoma primary and a stage IV metastasis. The patient subsequently recovered from his surgery and was put on pazopanib 800 mg once daily. He tolerated this pretty well at first. He had some fatigue, some moderate degree of diarrhea that was initially controlled with antidiarrheal medication, and demonstrated evidence of a disease reduction in his remaining adenopathy and adrenal gland. He started this therapy in 2014 and was on it for over 1 year, over which time he continued to have stable disease. However, over this period of time, fatigue built upas we commonly see—and episodes of diarrhea resulted in some increased weight loss and worsening fatigue, resulting in a dose reduction down to 600 mg. The patient continued to have evidence of overall stable disease, but slow increase in his tumor burden, particularly in his adrenal gland.
Then, about in the spring of 2016, he started developing increasing back pain. Workup revealed evidence of disease progression in his T9 lesion that had previously been radiated, as well as other spots in his spine, suggestive of worsening metastatic disease. At that point in time, the patient was switched from pazopanib to cabozantinib 60 mg once daily.
This case, if I can just comment, I think is atypical in that this is a young patient, 48 years old, but typical in that this patient had evidence of a disease that had spread to multiple organs and, therefore, was what we consider to be in an intermediate risk of presentation up front. His response to pazopanib was really exceptional: over 1 year of disease control even with a dose reduction. So, this was really suggesting, despite the intermediate-risk features, a robust dependence of that tumor on the VEGF pathway.
Case Scenario 1: A 50-year old male with relapse of metastatic RCC
January 2014
April 2016
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Sustained Treatment-Free Survival in RCC Seen With Nivolumab and Ipilimumab
April 30th 2024Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More